[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-386065-105":59,"doc-detail-386065-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","use-of-high-flow-nasal-cannula-oxygen-therapy-for-patients-with-terminal-cancer-at-the-end-of-life","Use of high-flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life","","Background: Few studies address high-flow nasal cannula (HFNC) use during the last weeks of life. Objective identification of HFNC status and associated clinical factors in end-of-life cancer patients. Methods: A single-center retrospective cohort study at a tertiary hospital in the Republic of Korea included patients with cancer who died between 2018 and 2020, initiating HFNC within 14 days before death. Patients were grouped as imminent (\u003C4 days) versus non-imminent (≥4 days) use. Results and conclusions report timing patterns and factors linked to imminent HFNC initiation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/use-of-high-flow-nasal-cannula-oxygen-therapy-for-patients-with-terminal-cancer-at-the-end-of-life/386065/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/use-of-high-flow-nasal-cannula-oxygen-therapy-for-patients-with-terminal-cancer-at-the-end-of-life/386065.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about HFNC use in terminal cancer?","Question",{"text":112,"@type":113},"It identifies how HFNC is used in the last weeks of life and which clinical factors are associated with its initiation timing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and grouped in the study?",{"text":117,"@type":113},"Patients with cancer who died between 2018 and 2020 and initiated HFNC within 14 days before death were included and categorized as imminent (\u003C4 days) or non-imminent (≥4 days).",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were independently associated with imminent HFNC use?",{"text":121,"@type":113},"Female sex, no palliative care consultation, no advance statements on life-sustaining treatment in person, and no resting dyspnea were independently associated with imminent HFNC initiation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},386065,1790643773,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1002/cam4 .6060  \nRESEAR CH ARTICLE  \nUse of high-flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life  \nJung Sun Kim1 | Jeongmi Shin2 | Nam Hee Kim3 | Sun Young Lee2,4 | Shin Hye Yoo3  | Bhumsuk Keam5  | Dae Seog Heo6  \n1Department of Internal Medicine, Chungnam National University Sejong Hospital, Sejong, Korea  \n2Public Healthcare Center, Seoul National University Hospital, Seoul, Korea  \n3Center for Palliative Care and Clinical  \nEthics, Seoul National University Hospital, Seoul, Korea 4Department of Medicine, Seoul National University College of Medicine, Seoul, Korea 5Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea  \n6Patient-Centered Clinical Research Coordinating Center, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea  \nCorrespondence  \nShin Hye Yoo, Center for Palliative Care and Clinical Ethics, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.  \nEmail: [ifi1024@gmail.com](ifi1024@gmail.com)  \nAbstract  \nBackground: Few studies have focused on high-flow nasal cannula (HFNC) usage in the last few weeks of life. The aim of this study was to identify the status of HFNC use in patients with cancer at the end of life and the relevant clinical factors.  \nMethods: We performed a retrospective cohort study in a tertiary hospital in the Republic of Korea. Among patients with cancer who died between 2018 and 2020, those who initiated HFNC within 14 days before death were included. Patients were categorized based on the time from HFNC initiation to death as imminent (\u003C4days) and non-imminent (≥4days) .  \nResults: Among the 2191 deceased patients with terminal cancer, 329 (15.0%) were analyzed. The median age of the patients was 66 years, and 62.9% were male. The leading cause of respiratory failure was pneumonia (70.2%), followed by pleural effusion (30.7%) and aggravation of lung neoplasms (18.8%) . Most patients were conscious (79.3%) and had resting dyspnea (76.3%) at HFNC initiation. Patients received HFNC therapy for a mean of 3.4 days in the last 2 weeks of life, and 62.6% initiated it within 4 days before death. Furthermore, female sex, no palliative care consultation, no advance statements in person on life-sustaining treatment, and no resting dyspnea were independently associated with the imminent use of HFNC.  \nConclusions: Many patients with cancer started HFNC therapy at the point of imminent death. However, efforts toward goal-directed use of HFNC at the endof-life stage are required.  \nKEYWORDS  \nend-of-life, high-flow nasal cannula, nasal cannula, neoplasm, oxygen inhalation therapy, retrospective study  \nJung Sun Kim and Jeongmi Shin contributed equally.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \nKIM et al.  \n|  \n14613  \n1 | INTRODUCTION  \nDyspnea is a prevalent symptom that 10%–70% of patients with cancer experience near death.1,2 Despite the advances in unraveling the pathophysiology and diagnostic workup of dyspnea, those in treatment are unparalleled.3 Thus, dyspnea still bothers patients with advanced cancer and remains a challenge for physicians.4 To date, pharmacologic agents, such as opioids, and non-pharmacological approaches, such as oxygen therapy, are widely used to manage dyspnea.3 In patients with advanced cancer, an initial approach with non-pharmacologic methods and treatment of underlying causes is recommended.5 However, oxygen therapy is narrowly recommended for patients with hypoxemic dyspnea.5  \nConventional oxygen therapy uses a nasal cannula or facial mask to deliver low oxygen flow. Additionally, noninvasive ventilation improved gas exchange, but tolerance was poor due to synchronizing difficulty, claustrophobia, and distinctive","cbCaia4bZtz6J6UO","https://ap.wps.com/l/cbCaia4bZtz6J6UO","pdf",862472,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods\n## Study design","[{\"question\":\"What question does the study address about HFNC use in terminal cancer?\",\"answer\":\"It identifies how HFNC is used in the last weeks of life and which clinical factors are associated with its initiation timing.\"},{\"question\":\"How were patients selected and grouped in the study?\",\"answer\":\"Patients with cancer who died between 2018 and 2020 and initiated HFNC within 14 days before death were included and categorized as imminent (\\u003c4 days) or non-imminent (≥4 days).\"},{\"question\":\"Which factors were independently associated with imminent HFNC use?\",\"answer\":\"Female sex, no palliative care consultation, no advance statements on life-sustaining treatment in person, and no resting dyspnea were independently associated with imminent HFNC initiation.\"}]","Use of high-flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life | PDF",1790272067,28]